The European Union has been slow to adapt to the rapidly changing landscape of cannabis legislation, lagging behind the United States and Canada, which have both legalized cannabis for recreational use.
A plethora of other countries around the world are also exploring the possibility of legalising cannabis, recognizing the potential economic, social, and medical benefits.
Many of these countries are in the EU, but their progressive ideas are not welcome in Brussels, it would appear.
The EU’s current policy on cannabis is outdated, ineffective, and ignores the latest scientific findings on the plant’s benefits and risks. Are the EU sponsored by alcohol companies?
Outdated and dangerous rhetoric
The EU’s policy on cannabis is rooted in the 1971 UN Single Convention on Narcotic Drugs, which categorizes cannabis as a Schedule I drug, implying that it has no accepted medical use and a high potential for abuse.
However, this policy is based on outdated scientific understanding and does not reflect the current reality of cannabis use and its potential applications.
Over the years, numerous studies have demonstrated the therapeutic potential of cannabis in treating various medical conditions, such as chronic pain, epilepsy, and cancer.
A recent study published in the European Journal of Pain revealed that cannabis is more effective than opioids for treating chronic pain, showcasing the potential to mitigate the ongoing opioid crisis.
Furthermore, the World Health Organization has acknowledged the medical benefits of cannabis and recommended rescheduling the drug under international treaties.
In terms of safety, cannabis is considered less harmful than both alcohol and tobacco, with a lower risk of addiction.
The National Institute on Drug Abuse discovered that cannabis use does not lead to long-term addiction, and its potential for abuse is significantly lower than that of other substances.
The EU’s reluctance to adapt its cannabis policy is not only ineffective but also harmful to its citizens.
The current policy criminalizes millions of individuals who use cannabis for medical or recreational purposes, leading to unnecessary stigmatization and burdening the legal system.
Additionally, the policy diverts law enforcement resources away from more serious crimes, resulting in inefficient allocation of resources.
No benefits for EU citizens
Legalizing cannabis in the EU would have numerous benefits, including providing a compassionate and fair policy for patients, consumers, and taxpayers.
By regulating the cannabis market, the EU could generate significant tax revenue, create new jobs, and ensure product quality and safety for consumers.
Legalisation would also promote research and innovation in the cannabis industry, further solidifying the EU’s position as a progressive and forward-thinking bloc.
It is high time for the European Union to catch up with the global trend of cannabis legalisation.
By doing so, the EU can demonstrate its commitment to progressive policies that prioritize the well-being of its citizens, encourage scientific advancement, and foster economic growth.
The time for change is now, and the EU must seize this opportunity to legalize cannabis and reap the numerous benefits that come with it.